OUR 9TH YEAR OF PROVIDING PROPRIETARY CAPITAL MARKETS INTELLIGENCE ON THE CANNABIS / HEMP / PSYCHEDELIC SECTORS

M&A Transactions

M&A Transaction Chart

Viridian publishes weekly data on M&A transactions in the Cannabis/CBD/Psychedelic industries. This data includes information about the buyer and seller (public/private, state/country location), deal size, deal structure (cash, stock, earn-out), pricing, share information, and deal implied valuation.

Week ended 01/27/2023

Week ended 01/27/2023

This Section is Only Available to Higher Tier Memberships

Please Purchase a Premium or Enterprise membership to see more.

M&A Transactions Commentary

Viridian publishes weekly insights on the M&A landscape in the Cannabis/CBD/Psychedelic industries. These insights typically highlight the most interesting/meaningful M&A transactions for that week, and commentary on market conditions, M&A deal structures, target regions for acquirers, and industry sectors ripe for consolidation.

Week ended 01/27/2023

The Largest Closed M&A Deal of the Week:

  • On January 24, 2023, 22nd Century Group inc. (XXII: Nasdaq), a leading competitor in the reduced nicotine tobacco, hemp/cannabis, and advanced plant technology sectors, announced the acquisition of privately held Pharmatech Ltd., a leading UK distributor of cannabinoids.
    • The total upfront consideration of $.65M was paid in cash. An additional three-year earnout provision is tied to revenue milestones.
    • Pharmatech’s products include CBD isolate and finished products like gummies, oils, and tinctures.
    • XXII intends to utilize its newly opened distribution facility in the Netherlands and the Pharmatech acquisition to scale its operations in the European consumer products sector.

Week ended 01/27/2023

This is the MA basic

Additional content is available to Premium and Enterprise users. Please purchase a higher tier membership to see more.